Valuation: Armata Pharmaceuticals, Inc.

Market Cap 173M 150M 140M 128M 241M 16.49B 245M 1.64B 644M 8.25B 649M 635M 27.48B P/E 2026 *
-1.24x
P/E 2027 * -3.51x
Enterprise Value 173M 150M 140M 128M 241M 16.49B 245M 1.64B 644M 8.25B 649M 635M 27.48B EV / Sales 2026 *
78.6x
EV / Sales 2027 * 62.9x
Free-Float
31.49%
Yield 2026 *
-
Yield 2027 * -
1 day-1.17%
1 week+1.32%
Current month+1.32%
1 month-4.76%
3 months-44.58%
6 months-41.18%
Current year-26.75%
1 week 4.51
Extreme 4.51
5.7
1 month 3.48
Extreme 3.48
5.7
Current year 3.48
Extreme 3.48
14.98
1 year 2.36
Extreme 2.36
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 2023-07-10
Director of Finance/CFO 42 2024-08-15
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 2019-05-08
Director/Board Member 66 2020-02-11
Director/Board Member 51 2020-02-11
Date Insider Type Main position Quantity % Market Cap.
7/10/26 Tax

Chief Executive Officer

-14,041 0.0382%
4/24/26 Free

Director

51,280 0.1400%
3/9/26 Free

Director

25,640 0.0704%
Change 5-day change 1-year change 3-year change Capi.($)
-2.34%+1.32%+90.90%+18.56% 173M
+4.21%+25.62%+77.96%+111.62% 68.12B
+0.50%+2.95%+34.94%+69.77% 55.18B
+2.78%+36.66%+23.00%+526.16% 28.63B
+0.57%+19.05%+57.08%+5.18% 23.99B
-0.93%+2.45%-16.89%-12.86% 23.53B
-0.35%+7.18%+44.14%-22.28% 18.45B
-2.04%+9.24%+31.14%+650.71% 16.44B
+7.26%+25.47%+221.03%+383.67% 15.83B
-2.05%-0.13%+40.40%+156.84% 13.4B
Average +0.77%+8.96%+60.37%+188.74% 26.37B
Weighted average by Cap. +1.54%+11.47%+54.04%+169.87%

Financials

2026 *2027 *
Net sales 2.2M 1.9M 1.78M 1.63M 3.07M 210M 3.11M 20.88M 8.19M 105M 8.26M 8.08M 350M 2.75M 2.38M 2.23M 2.03M 3.83M 262M 3.89M 26.09M 10.24M 131M 10.33M 10.1M 437M
Net income -172M -149M -139M -127M -240M -16.39B -243M -1.63B -640M -8.2B -645M -631M -27.32B -66.35M -57.44M -53.69M -49.07M -92.47M -6.33B -93.91M -630M -247M -3.17B -249M -244M -10.54B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26-08-10 US$4.600 -2.34% 81,560
26-08-07 US$4.710 +0.21% 37,501
26-08-06 US$4.700 0.00% 103,857
26-08-05 US$4.700 +0.43% 103,896
26-08-04 US$4.680 -7.33% 276,234
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.710USD
Average target price
17.50USD
Spread / Average Target
+271.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock